IDEXX Laboratories Announces Second Quarter Results
WESTBROOK, Maine, July 31, 2020 /PRNewswire/ --
-- Reports revenue growth of 3% on a reported basis and 4% on an organic
basis driven by Companion Animal Group Diagnostics recurring revenue
growth of 7% reported and organic
-- Revenue results supported by global "V-shaped" recovery in the pet
healthcare market
-- Delivers EPS of $1.72, representing 20% growth on a reported basis and
23% on a comparable constant currency basis, reflecting solid revenue
gains and benefits from proactive cost controls
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, today announced second quarter results, as well as business and market condition updates related to the 2019 novel coronavirus (COVID-19) pandemic.
Second Quarter Results
The Company reports revenues of $638 million for the second quarter of 2020, an increase of 3% on a reported and 4% on an organic basis. Second quarter results were driven by Companion Animal Group ("CAG") Diagnostics recurring revenue growth of 7% reported and organic, supported by high single-digit organic gains in both U.S. and International markets. Overall growth in the second quarter benefited by approximately 1% from revenues associated with OPTI Medical Systems COVID-19 human PCR testing. Second quarter results were moderated by declines in new CAG instrument placement levels and Water business revenues, including pressures in non-compliance water testing, impacted by factors related to the COVID-19 pandemic.
Earnings per diluted share ("EPS") was $1.72 for the second quarter, reflecting benefits from strong CAG Diagnostics recurring revenue growth and lower operating expenses, reflecting proactive cost control efforts, which supported 380 basis points of operating margin improvement on a reported basis compared to prior-year levels and 410 basis points of improvement on a constant currency basis.
"We are very pleased to report excellent second quarter financial results, supported by a sharp, global recovery in our CAG business and outstanding efforts by the IDEXX team to sustain high levels of service to our customers through the COVID-19 pandemic. These results confirm the health and resilience of the global companion animal healthcare market, supported by the continued deepening of the pet-owner bond," said Jay Mazelsky, the Company's President and Chief Executive Officer. "We are encouraged by recent market trends and confident in our ability to effectively manage through the near-term challenges presented by the COVID-19 pandemic, as we continue to execute our strategy to advance the standard of care for companion animal healthcare globally."
COVID-19 Pandemic Update
The primary impacts of the COVID-19 pandemic have been seen in IDEXX's CAG business. While veterinary care is widely recognized as an "essential" service, stay-at-home policies deployed to combat the spread of COVID-19 constrained visits to veterinary practices significantly in late March through early April, pressuring diagnostic testing volumes. Restrictions on sales professionals' access to veterinary clinics also contributed to deferrals on new CAG instrument placements.
As stay-at-home policies were relaxed, there was significant improvement in clinical visit activity which accelerated through the second quarter. Weekly U.S. companion animal practice data, available in the Q2 2020 Earnings Snapshot accessible on the IDEXX website, www.idexx.com/investors, show improvement in same store clinical visit trends since mid-April. Same store clinical visit growth was 7% in June, supported by high growth in wellness visits. Solid same store clinical visit gains have continued in July, reflected in 6% same store clinical visit growth for the three-week period ended July 17.
Companion animal market improvement trends globally have supported a strong recovery in demand for CAG diagnostic products and services. Global CAG Diagnostics recurring revenues which declined ~16% in April, increased ~8% in May and grew ~30% in June, in part supported by pent-up demand for diagnostic testing.
While these trends are encouraging, potential effects related to ongoing COVID-19 case management efforts are challenging to predict and may pressure future revenues should enhanced social distancing policies and higher infection rates impact veterinary clinic operations in certain regions.
In addition to impacts on IDEXX's CAG business, the Company has also seen pressure on Water testing volumes. There was some disruption to compliance Water testing early in the second quarter related to business lockdown effects, as well as beach and pool closures. In addition, approximately 20% of our Water revenues are related to non-compliance testing, which has seen declines related to reduced overall business activity and prioritization of laboratory spending. We anticipate that near-to-moderate-term demand for non-compliance testing will continue to be impacted by pandemic and related economic pressures.
In managing IDEXX businesses, the Company continues to provide high levels of service delivery and product support for customers during this time and maintains high health and safety standards to protect its employees and ensure business continuity. In an effort to continue to protect the health and safety of our workforce and their families and communities, the majority of IDEXX employees continue to work remotely and travel remains highly restricted. In this context, the Company has introduced new employee benefits to support remote workers. Given improved market and business trends, the Company has discontinued temporary reductions in employee salaries and benefits and Board of Directors compensation.
Due to the continued uncertainty around the scope and duration of the pandemic and the timing of a global recovery, the Company is unable, at this time, to reliably estimate the future impact on business operations and financial results.
Second Quarter Performance Highlights
Companion Animal Group
The Companion Animal Group generated 3% reported and 4% organic revenue growth for the quarter, supported by CAG Diagnostics recurring revenue growth of 7% on a reported and organic basis. Growth across IDEXX's major modalities improved through the second quarter, reflecting the broader market recovery for clinical visits and related diagnostic products and services. Overall CAG revenue growth was constrained by new instrument placement declines, resulting from continued restrictions on access to some veterinary practices and deferral of purchasing decisions. Despite these impacts, IDEXX's premium instrument installed base expanded 14% compared to the prior year, supported by high customer retention levels.
-- IDEXX VetLab® consumables generated 12% reported and 13% organic
revenue growth, supported by ongoing expansion of our global premium
instrument installed base, continued strong customer retention,
increases in testing utilization and moderate net price gains.
-- Reference laboratory diagnostic and consulting services generated 7%
reported and 6% organic revenue growth, supported by volume gains with
existing customers, moderate net price realization and benefits from net
new customer additions.
-- Rapid assay products revenues declined 6% on a reported basis and 5% on
an organic basis, impacted primarily by early quarter volume pressure
related to the COVID-19 pandemic, as well as unfavorable revenue impacts
related to promotional program timing.
Veterinary software, services and diagnostic imaging systems revenue declined 4% on a reported and 3% on an organic basis, supported by double-digit growth in subscription-based service revenues, moderated by declines in new veterinary software and diagnostic imaging systems placements.
Water
Water revenues declined 19% on a reported basis and 16% on an organic basis for the quarter, including reductions in non-compliance testing volumes due to restrictions in business operations and closures related to the COVID-19 pandemic, and the unfavorable impact from the reversal of accelerated customer stocking orders related to the COVID-19 pandemic in the first quarter of approximately $2 million which reduced revenue growth by 7%.
Livestock, Poultry and Dairy ("LPD")
LPD revenues declined 3% on a reported basis and increased by 2% on an organic basis for the second quarter, including the unfavorable impact from the reversal of accelerated customer stocking orders related to the COVID-19 pandemic in the first quarter of approximately $2.5 million which reduced revenue growth by 8%. LPD results were supported by improvements in core swine testing volumes, continued benefits from new African Swine Fever diagnostic testing programs in Asia, and growth in poultry testing. These gains were constrained by lower herd health screening levels, compared to strong prior-year results.
Gross Profit and Operating Profit
Gross profits increased 6% on a reported basis and 8% on a constant currency basis. Gross margin of 59.5% increased 180 basis points compared to prior-year period results on a reported basis and 210 basis points on a constant currency basis. Gross margin results reflected favorable mix from strong consumable revenue and lower instrument revenue, reference laboratory cost controls and productivity improvement, as well as net benefits from moderate price gains.
Operating margin was 30.3% in the quarter, 380 basis points higher than the prior-year period results on a reported basis and 410 basis points higher on a constant currency basis, supported by operating expense leverage on stronger than expected revenue growth. Operating expenses declined 4% on a reported and 2% on a constant currency basis, driven by disciplined cost management to mitigate potential impacts from the COVID-19 pandemic and lower health benefit costs from delayed employee healthcare visits. Operating expenses included an estimated $13 million in benefit from temporary salary and employee benefit reductions that have now been discontinued. The Company plans to advance prioritized investments in support of its growth strategy in the second half of 2020, while maintaining a prudent approach to overall cost management.
2020 Financial Outlook
The Company is maintaining suspension of full-year 2020 guidance due to the unpredictability of potential future impacts from the COVID-19 pandemic.
Conference Call and Webcast Information
IDEXX Laboratories, Inc. will be hosting a conference call today at 8:30 a.m. (EDT) to discuss its second quarter 2020 results and management's outlook. To participate in the conference call, dial 1-888- 771-4371 or 1-847-585-4405 and reference confirmation number 49844277. Individuals can access a live webcast of the conference call through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. (EDT) on that day via the same link and will remain available for one year.
2020 Virtual Investor Day
IDEXX Laboratories, Inc. will host its 2020 virtual Investor Day on Thursday, August 13, 2020 from 10:00 am to 12:00 pm (EDT). A live audio webcast and accompanying slide presentations will be available at www.idexx.com/investors. An archived webcast replay of the event will be available approximately one hour following the event at www.idexx.com/investors.
About IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc. is a member of the S&P 500® Index and is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for livestock and poultry and tests for the quality and safety of water and milk and point-of-care and laboratory diagnostics for human medicine. Headquartered in Maine, IDEXX employs more than 9,000 people and offers products to customers in over 175 countries. For more information about IDEXX, visit: www.idexx.com.
Note Regarding Forward-Looking Statements
This earnings release contains statements about the Company's business prospects and estimates of the Company's financial results for future periods that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements are included above under "Second Quarter Results," "COVID-19 Pandemic Update" and "Gross Profit and Operating Profit" and elsewhere and can be identified by the use of words such as "expects", "may", "anticipates", "intends", "would", "will", "plans", "believes", "estimates", "projected", "should", and similar words and expressions. Our forward-looking statements include statements relating to, among other things, the impact of the COVID-19 pandemic and the Company's planned future investments and cost-management approach. These statements are intended to provide management's expectation of future events as of the date of this earnings release; are based on management's estimates, projections, beliefs and assumptions as of the date of this earnings release; and are not guarantees of future performance. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, among other things, the adverse impact, and the duration, of the effects of the ongoing COVID-19 pandemic on our business, results of operations, liquidity, financial condition and stock price, as well as the other matters described under the headings "Business," "Risk Factors," "Legal Proceedings," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Quantitative and Qualitative Disclosures About Market Risk" in the Company's Annual Report on Form 10-K for the year ended December 31, 2019 and in the corresponding sections of the Company's Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020 and June 30, 2020, as well as those described from time to time in the Company's other filings with the U.S. Securities and Exchange Commission available at www.sec.gov. The Company specifically disclaims any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Statement Regarding Non-GAAP Financial Measures
The following defines terms and conventions and provides reconciliations regarding certain measures used in this earnings release and/or the accompanying earnings conference call that are not required by, or presented in accordance with, generally accepted accounting principles in the United States of America ("GAAP"), otherwise referred to as non-GAAP financial measures. To supplement the Company's consolidated results presented in accordance with GAAP, the Company has disclosed non-GAAP financial measures that exclude or adjust certain items. Management believes these non-GAAP financial measures provide useful supplemental information for its and investors' evaluation of the Company's business performance and liquidity and are useful for period-over-period comparisons of the performance of the Company's business and its liquidity and to the performance and liquidity of our peers. While management believes that these non-GAAP financial measures are useful in evaluating the Company's business, this information should be considered as supplemental in nature and should not be considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP. In addition, these non-GAAP financial measures may not be the same as similarly titled measures reported by other companies.
Constant currency - Constant currency references are non-GAAP financial measures which exclude the impact of changes in foreign currency exchange rates and are consistent with how management evaluates our performance and comparisons with prior and future periods. We estimated the net impacts of currency on our revenue, gross profit, operating profit, and EPS results by restating results to the average exchange rates or exchange rate assumptions for the comparative period, which includes adjusting for the estimated impacts of foreign currency hedging transactions and certain impacts on our effective tax rates. These estimated currency changes impacted second quarter 2020 results as follows: decreased gross profit growth by approximately 2%, decreased gross profit margin growth by 30 basis points, decreased operating expense growth by 2%, decreased operating profit growth by 2%, decreased operating profit margin growth by 30 basis points, and decreased EPS growth by 3%. Estimated currency changes also decreased first half 2020 EPS growth by 3%. Constant currency revenue growth represents the percentage change in revenue during the applicable period, as compared to the prior-year period, excluding the impact of changes in foreign currency exchange rates. See the supplementary analysis of results below for revenue percentage change from currency for the three months ended June 30, 2020.
Growth and organic revenue growth - All references to growth and organic growth refer to growth compared to the equivalent prior-year period unless specifically noted. Organic revenue growth is a non-GAAP financial measure that excludes the impact of changes in foreign currency exchange rates and revenue from certain business acquisitions. See the supplementary analysis of results below for a reconciliation of reported revenue growth to organic revenue growth for the three and six months ended June 30, 2020. The percentage change in revenue resulting from acquisitions represents incremental revenues attributable to business acquisitions that have occurred since the beginning of the prior-year period. We exclude only acquisitions that are considered to be a business from organic revenue growth. For more detail on what acquisitions we consider to be a business in computing organic growth, please see Management's Discussion and Analysis of Financial Conditions and Results of Operations, Non-GAAP Financial Measures, contained in the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2020.
Comparable constant currency EPS growth - Comparable constant currency EPS growth is a non-GAAP financial measure that excludes the impact of changes in foreign currency exchange rates and the tax benefits of share-based compensation activity under ASU 2016-09 and non-recurring or unusual items (if any). Management believes comparable constant currency EPS growth is a more useful way to measure the Company's business performance than EPS growth because it enables better period-over-period comparisons of the fundamental financial results by excluding items that vary independent of performance and provides greater transparency to investors regarding a key metric used by management. Share-based compensation tax benefits increased second quarter 2020 EPS by $0.06 per share, first half 2020 EPS by $0.13 per share, second quarter 2019 EPS by $0.06 per share, and first half 2019 EPS by $0.12 per share. These impacts and those described in the constant currency note above reconcile reported EPS growth to comparable constant currency EPS growth for the second quarter and first half of 2020.
Free cash flow - Free cash flow is a non-GAAP financial measure and means, with respect to a measurement period, the cash generated from operations during that period, reduced by the Company's investments in property and equipment. Management believes free cash flow is a useful measure because it indicates the cash the operations of the business are generating after appropriate reinvestment for recurring investments in property and equipment that are required to operate the business. See the supplementary analysis of results below for our calculation of free cash flow for the six months ended June 30, 2020 and 2019.
Debt to Adjusted EBITDA (Leverage Ratios) - Adjusted EBITDA, gross debt, and net debt are non-GAAP financial measures. Adjusted EBITDA is a non-GAAP financial measure of earnings before interest, taxes, depreciation, amortization, non-recurring transaction expenses incurred in connection with acquisitions, share-based compensation expense, and certain other non-cash losses and charges. Management believes that reporting Adjusted EBITDA, gross debt and net debt in the Debt to Adjusted EBITDA ratios provides supplemental analysis to help investors further evaluate the Company's business performance and available borrowing capacity under the Company's credit facility. For further information on how Adjusted EBITDA and the Debt to Adjusted EBITDA ratios are calculated, see the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2020.
Contact: John Ravis, Investor Relations, 1-207-556-8155
IDEXX Laboratories, Inc. and Subsidiaries
Condensed Consolidated Statement of Operations
Amounts in thousands except per share data (Unaudited)
Three Months Ended
Six Months Ended
June 30, June 30, June 30, June 30,
2020 2019 2020 2019
Revenue:
Revenue $637,592 $620,103 $1,263,928 $1,196,159
Expenses and Income:
Cost of revenue 258,250 262,250 524,996 506,709
Gross profit 379,342 357,853 738,932 689,450
Sales and marketing 94,181 101,364 210,324 207,948
General and administrative 60,268 59,955 126,080 120,316
Research and development 31,645 32,259 64,955 63,773
Income from operations 193,248 164,275 337,573 297,413
Interest expense, net (9,426) (8,153) (16,978) (16,499)
Income before provision for income
taxes 183,822 156,122 320,595 280,914
Provision for income taxes 34,826 30,421 59,743 52,504
Net Income:
Net income 148,996 125,701 260,852 228,410
Less: Noncontrolling interest in
subsidiary's earnings 56 (5) 85 23
Net income attributable to
stockholders $148,940 $125,706 $260,767 $228,387
Earnings per share: Basic $1.75 $1.46 $3.06 $2.65
Earnings per share: Diluted $1.72 $1.43 $3.01 $2.61
Shares outstanding: Basic 85,134 86,215 85,282 86,210
Shares outstanding: Diluted 86,402 87,615 86,568 87,594
IDEXX Laboratories, Inc. and Subsidiaries
Selected Operating Information (Unaudited)
Three Months Ended
Six Months Ended
June 30, June 30, June 30, June 30,
2020 2019 2020 2019
Operating Ratios
Gross profit 59.5 57.7
% % 58.5
% 57.6
%
(as a percentage of Sales, marketing, general and 24.2 26.0
revenue): administrative expense % % 26.6
% 27.4
%
Research and development expense 5.0 5.2
% % 5.1
% 5.3
%
Income from operations(1) 30.3 26.5
% % 26.7
% 24.9
%
(1)Amounts presented may not recalculate due to rounding.
IDEXX Laboratories, Inc. and Subsidiaries
Segment Information
Amounts in thousands (Unaudited)
Three Months Ended Three Months Ended
June 30, Percent of June 30, Percent of
2020 Revenue 2019 Revenue
Revenue:
CAG $566,100 $547,349
Water 28,116 34,764
LPD 32,244 33,104
Other 11,132 4,886
Total $637,592 $620,103
Gross Profit
CAG $334,467 59.1 $311,295 56.9
(1)
:
% %
Water 19,678 70.0 24,861 71.5
% %
LPD 18,839 58.4 19,679 59.4
% %
Other 6,358 57.1 2,018 41.3
% %
Total $379,342 59.5 $357,853 57.7
% %
Income from Operations
CAG $167,969 29.7 $141,190 25.8
(1)
:
% %
Water 12,258 43.6 16,722 48.1
% %
LPD 8,249 25.6 6,568 19.8
% %
Other 4,772 42.9 (205) (4.2)
% %
Total $193,248 30.3 $164,275 26.5
% %
Six Months Ended Six Months Ended
June 30, Percent of June 30,
2020 Revenue 2019
Percent of
Revenue
Revenue:
CAG $1,118,096 $1,056,267
Water 62,265 65,074
LPD 66,398 64,610
Other 17,169 10,208
Total $1,263,928 $1,196,159
Gross Profit
CAG $643,810 57.6
(1)
:
% $598,965 %
56.7
Water 44,427 71.4
% 47,008 %
72.2
LPD 41,151 62.0
% 38,728 %
59.9
Other 9,544 55.6
% 4,749 %
46.5
Total $738,932 58.5
% $689,450 %
57.6
Income from Operations
CAG $286,628 25.6
(1)
:
% $252,909 %
23.9
Water 28,140 45.2
% 30,537 %
46.9
LPD 17,912 27.0
% 12,857 %
19.9
Other 4,893 28.5
% 1,110 %
10.9
Total $337,573 26.7
% $297,413 %
24.9
(1) Effective January 1, 2020, we
modified our management reporting to the
Chief Operating Decision Maker to
provide a more comprehensive view of the
performance of our operating segments by
including costs that were previously not
allocated to our segments. Prior to
January 1, 2020, certain costs were not
allocated to our operating segments and
were instead reported under the caption
"Unallocated Amounts". These costs
included costs primarily consisting of
our R&D function, regional or country
expenses and unusual items. Corporate
support function costs (such as
information technology, facilities,
human resources, finance and legal),
health benefits and incentive
compensation were charged to our
business segments at pre-determined
budgeted amounts or rates. Beginning
January 1, 2020, the segments will
reflect these actual costs allocated to
the segment based on various allocation
methods, including revenue and
headcount. Foreign exchange losses on
settlements of foreign currency
denominated transactions are not
allocated to our operating segments and
are instead reported under our Other
reporting segment.
IDEXX Laboratories, Inc. and Subsidiaries
Revenues and Revenue Growth Analysis by Product and Service Categories and by Domestic and International Markets
Amounts in thousands (Unaudited)
Three Months Ended
June 30, June 30, Dollar Reported Percentage Percentage Organic
2020 2019 Change Revenue Change Change from Revenue
Growth(1) from Currency Acquisitions Growth(1)
Net Revenue
CAG $566,100 $547,349 $18,751 3.4 (1.0) 0.7 3.8
% %
% %
United States 387,113 367,031 20,082 5.5 1.0 4.5
%
% %
International 178,987 180,318 (1,331) (0.7) (3.1) 2.3
%
% %
Water 28,116 34,764 (6,648) (19.1) (3.0) (16.2)
%
% %
United States 13,935 16,759 (2,824) (16.8) (16.8)
% %
International 14,181 18,005 (3,824) (21.2) (5.8) (15.5)
%
% %
LPD 32,244 33,104 (860) (2.6) (4.3) 1.7
%
% %
United States 3,242 3,309 (67) (2.0) (2.0)
% %
International 29,002 29,795 (793) (2.6) (4.8) 2.2
%
% %
Other 11,132 4,886 6,246 127.8 127.8
% %
Total Company $637,592 $620,103 $17,489 2.8 (1.3) 0.6 3.6
% %
% %
United States 405,998 388,875 17,123 4.4 0.9 3.5
%
% %
International 231,594 231,228 366 0.2 (3.6) 3.8
% %
%
---
Three Months Ended
June 30, June 30, Dollar Reported Percentage Percentage Organic
2020 2019 Change Revenue Change Change from Revenue
Growth(1) from Currency Acquisitions Growth(1)
Net CAG Revenue
CAG Diagnostics recurring $510,254 $477,431 $32,823 6.9 (1.1) 0.8 7.2
revenue: % % % %
IDEXX VetLab consumables 196,061 175,159 20,902 11.9 (1.6) 13.5
%
% %
Rapid assay products 64,658 68,605 (3,947) (5.8) (0.6) (5.1)
%
% %
Reference laboratory diagnostic 228,816 213,892 14,924 7.0 (0.8) 1.7 6.1
and consulting services
% %
% %
CAG Diagnostics services and 20,719 19,775 944 4.8 (1.3) 6.1
accessories
% %
%
CAG Diagnostics capital - 18,871 31,526 (12,655) (40.1) (1.0) (39.1)
instruments % % %
Veterinary software, services and 36,975 38,392 (1,417) (3.7) (0.3) (3.4)
diagnostic imaging systems % %
%
Net CAG revenue $566,100 $547,349 $18,751 3.4 (1.0) 0.7 3.8
% % % %
(1)See Statements Regarding Non-GAAP Financial Measures, above. Amounts presented may not recalculate due to rounding.
IDEXX Laboratories, Inc. and Subsidiaries
Revenues and Revenue Growth Analysis by Product and Service Categories and by Domestic and International Markets
Amounts in thousands (Unaudited)
Six Months Ended
June 30, June 30, Dollar Reported Percentage Percentage Organic
2020 2019 Change Revenue Change from Change from Revenue
Growth(1) Currency Acquisitions Growth(1)
Net Revenue
CAG $1,118,096 $1,056,267 $61,829 5.9 (1.0) 0.7 6.1
% % % %
United States 760,388 704,905 55,483 7.9 1.1 6.8
% % %
International 357,708 351,362 6,346 1.8 (2.9) 4.7
% % %
Water 62,265 65,074 (2,809) (4.3) (3.0) (1.4)
% % %
United States 30,876 31,363 (487) (1.6) (1.6)
% %
International 31,389 33,711 (2,322) (6.9) (5.7) (1.2)
% % %
LPD 66,398 64,610 1,788 2.8 (4.0) 6.8
% % %
United States 7,019 6,572 447 6.8 6.8
% %
International 59,379 58,038 1,341 2.3 (4.4) 6.8
% % %
Other 17,169 10,208 6,961 68.2 68.2
% %
Total Company $1,263,928 $1,196,159 $67,769 5.7 (1.2) 0.6 6.3
% % % %
United States 802,781 747,163 55,618 7.4 1.0 6.4
% % %
International 461,147 448,996 12,151 2.7 (3.3) 6.0
% % %
---
Six Months Ended
June 30, June 30, Dollar Reported Percentage Percentage Organic
2020 2019 Change Revenue Change from Change from Revenue
Growth(1) Currency Acquisitions Growth(1)
Net CAG Revenue
CAG Diagnostics recurring $998,179 $921,222 $76,957 8.4 (1.0) 0.8 8.5
revenue: % % % %
IDEXX VetLab consumables 384,774 342,370 42,404 12.4 (1.4) 13.8
% % %
Rapid assay products 122,088 123,036 (948) (0.8) (0.6) (0.2)
% % %
Reference laboratory diagnostic 449,077 416,550 32,527 7.8 (0.8) 1.8 6.8
and consulting services
% % % %
CAG Diagnostics services and 42,240 39,266 2,974 7.6 (1.4) 9.0
accessories
% % %
CAG Diagnostics capital - 42,704 60,275 (17,571) (29.2) (1.1) (28.0)
instruments % % %
Veterinary software, services and 77,213 74,770 2,443 3.3 (0.3) 3.5
diagnostic imaging systems % % %
Net CAG revenue $1,118,096 $1,056,267 $61,829 5.9 (1.0) 0.7 6.1
% % % %
(1)See Statements Regarding Non-GAAP Financial Measures, above. Amounts presented may not recalculate due to rounding.
IDEXX Laboratories, Inc. and Subsidiaries
Condensed Consolidated Balance Sheet
Amounts in thousands (Unaudited)
June 30, December 31,
2020 2019
Assets: Current Assets:
Cash and cash equivalents $105,293 $90,326
Accounts receivable, net 320,320 269,312
Inventories 229,377 195,019
Other current assets 124,622 124,982
Total current assets 779,612 679,639
Property and equipment, net 550,895 533,845
Other long-term assets, net 630,206 618,991
Total assets $1,960,713 $1,832,475
Liabilities and
Stockholders'
Equity: Current Liabilities:
Accounts payable $73,903 $72,172
Accrued liabilities 308,768 322,938
Line of credit 121,596 288,765
Deferred revenue 36,317 41,462
Total current liabilities 540,584 725,337
Long-term debt 899,562 698,910
Other long-term liabilities, net 247,167 230,403
Total long-term liabilities 1,146,729 929,313
Total stockholders' equity 272,963 177,473
Noncontrolling interest 437 352
Total stockholders' equity 273,400 177,825
Total liabilities and stockholders'
equity $1,960,713 $1,832,475
IDEXX Laboratories, Inc. and Subsidiaries
Select Balance Sheet Information (Unaudited)
June 30, March 31, December 31, September 30, June 30,
2020 2020 2019 2019 2019
Selected Balance Sheet
Information: Days sales outstanding(1) 44.4 41.5 40.5 41.8 41.7
Inventory turns(2) 1.6 1.9 2.2 2.0 2.1
(1)Days sales outstanding represents the average of the accounts
receivable balances at the beginning and end of each quarter divided
by revenue for that quarter, the result of which is then multiplied
by 91.25 days.
(2)Inventory turns represent inventory-related cost of product
revenue for the twelve months preceding each quarter-end divided by
the average inventory balances at the beginning and end of each
quarter.
IDEXX Laboratories, Inc. and Subsidiaries
Condensed Consolidated Statement of Cash Flows
Amounts in thousands (Unaudited)
Six Months Ended
June 30, June 30,
2020 2019
Operating: Cash Flows from Operating
Activities:
Net income $260,852 $228,410
Non-cash charges 70,576 60,381
Changes in assets and liabilities (95,415) (117,311)
Net cash provided by operating
activities 236,013 171,480
Investing: Cash Flows from Investing
Activities:
Purchases of property and
equipment (73,558) (71,987)
Acquisition of intangible assets
and business (668) (304)
Net cash used by investing
activities (74,226) (72,291)
Financing: Cash Flows from Financing
Activities:
Repayments on revolving credit
facilities, net (167,692) (147,519)
Issuance of senior notes 200,000 100,000
Debt issuance costs (4,988) (142)
Payment of acquisition-related
contingent consideration (1,080) (1,695)
Repurchases of common stock (182,815) (74,994)
Proceeds from exercises of stock
options and employee stock
purchase plans 20,613 19,653
Shares withheld for statutory tax
withholding on restricted stock (8,668) (7,572)
Net cash used by financing
activities (144,630) (112,269)
Net effect of changes in exchange
rates on cash (2,190) 131
Net increase (decrease) in cash
and cash equivalents 14,967 (12,949)
Cash and cash equivalents,
beginning of period 90,326 123,794
Cash and cash equivalents, end of
period $105,293 $110,845
IDEXX Laboratories, Inc. and Subsidiaries
Free Cash Flow
Amounts in thousands except per share data (Unaudited)
Six Months Ended
June 30, June 30,
2020 2019
Free Cash Net cash provided by
Flow: operating activities $236,013 $171,480
Investing cash flows
attributable to purchases of
property and equipment (73,558) (71,987)
Free cash flow(1) $162,455 $99,493
(1)See Statements Regarding Non-GAAP Financial Measures, above.
IDEXX Laboratories, Inc. and Subsidiaries
Common Stock Repurchases
Amounts in thousands except per share data (Unaudited)
Three Months Ended Six Months Ended
June 30, June 30, June 30, June 30,
2020 2019 2020 2019
Shares repurchased in the open market 86 721 353
Shares acquired through employee surrender for statutory tax withholding 1 30 37
Total shares repurchased 87 751 390
Cost of shares repurchased in the open market
$- $20,285 $179,623 $74,147
Cost of shares for employee surrenders 65 169 8,669 7,572
Total cost of shares $65 $20,454 $188,292 $81,719
Average cost per share - open market repurchases
$- $235.94 $249.20 $209.81
Average cost per share - employee surrenders $312.19 $249.77 $288.94 $207.16
Average cost per share - total $312.19 $236.04 $250.79 $209.56
View original content to download multimedia:http://www.prnewswire.com/news-releases/idexx-laboratories-announces-second-quarter-results-301103564.html
SOURCE IDEXX Laboratories, Inc.
